Jianfeng Group has been listed for 25 years.
Release time:
2020-08-14
Jianfeng Group has been listed for 25 years
Zhejiang Daily reporter Liu Wei
Editor's note: 1993 7 28 , Jianfeng Group's public shares were listed on the Shanghai Stock Exchange, becoming a milestone in the development history of Jianfeng 60 years. A few days ago, the "Zhejiang Daily" published an article, the peak 25 years to stick to the main business, innovation and development of the deeds of the report. This newspaper is reproduced.
7 , Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Group"), located at 88 Wujiang East Road, Jinhua City, celebrated the 34th anniversary of the company's listing 25.
Jianfeng Group is not only the first listed company in China's cement industry, but also the earliest listed company in Zhejiang Province that is still listed on A shares. Judging from the history of 25 years, although A shares have experienced several rounds of bulls and bears, the stock price trend of Jianfeng Group has remained in the overall stable upward channel.
Don't chase hot spots, avoid delinquency
"After the listing of the Peak Group in order to overcome the cyclical characteristics of the cement industry, but also carried out some diversification exploration. At that time, there were many opportunities to make money, but many of our areas were briefly tried and immediately quit, the overall or around the two main businesses." Jianfeng Group Chairman Jiang Xiaomeng told reporters.
Any project that makes money is a common problem for many enterprises after listing. In particular, some listed companies often rub against the concept of hot spots, which leads to sharp rise and fall of stock prices and finally ends up in a feather.
1994 November , Jianfeng Group successfully bought Jinhua MSG Factory, a state-owned enterprise, with 1400 yuan and began to produce soy sauce and rice vinegar. In the same year, the peak communication cable Co., Ltd. was completed and put into operation. "At that time, there were many fields, including ceramics, electronic instruments, mineral water, toll roads and so on." Jiang Xiaomeng recalled, "But we finally found that these were not what the peak really needed, and we quickly withdrew." Jianfeng Group will eventually break the direction of the pharmaceutical industry.
In 1998 8 , Jianfeng Group purchased the then Jinhua Biochemical Pharmaceutical Factory and established Jianfeng Pharmaceutical Co., Ltd. on this basis. At present, the operating income of the peak pharmaceutical sector has exceeded 40%, becoming one of the main businesses of the peak group. "At present, our two major businesses, cement and medicine, account for 90% of the revenue. In addition, there are two major businesses, health and trade logistics, both of which are related to the main business." Jiang Xiaomeng concluded that the key to the development of the peak lies in not chasing hot spots, not robbing quick money and sticking to industry. In recent years, there have been many examples of listed companies going from real to virtual. Jianfeng Group has also carried out a series of investment mergers and acquisitions in recent years, but it has always focused on the two main businesses, which also makes the company's performance improve steadily, so as to avoid the ups and downs of the company's efficiency.
A listed companies do not pay dividends to shareholders for a long time, which is called "iron rooster" by the market ".
25 , the total assets and net assets of Jianfeng Group increased nearly 30 times and 28 times respectively. 2017 The company realized net profit attributable to owners of the parent company 3.48 .9 billion yuan, and earnings per share reached 1.01 yuan, a record high since listing. What is even more rare is that the company has continuously given back to investors. In the past 10 years, 9 has paid cash dividends. Since Jianfeng Group went public, its accumulated cash dividends have reached .7 billion yuan. "Listed companies should develop steadily, while insisting on giving investors returns and balancing cash dividends with the long-term development of the company. This is a win-win situation for investors to share the dividends of corporate growth and for the company to continue to develop healthily." Jiang Xiaomeng said.
5 , after the "New Country Nine Articles" first proposed "encouraging listed companies to establish a market value management system", market value management has become the focus of the capital market: listed companies hope to use this To achieve industrial transformation and upgrading, shareholders hope to maximize value, but in actual operations, there have been many violations of laws and regulations in the name of "market value management. In recent years, a number of listed companies have been investigated by the CSRC because of market manipulation and insider trading in the name of market value management.
2020 . "As the listed company with the longest listing history of A shares in Zhejiang Province, we feel the pressure and responsibility." Jiang Xiaomeng said, "there are many listed companies that are better than us, and the peak should also learn from the excellent listed companies and strive to realize the dream of 'one hundred years' peak."
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31